Help us: Donate
Follow us on:



Tag: Rapalogs

February 02, 2020
The January edition of Journal Club, hosted by Dr. Oliver Medvedik, took a look at the results of a recent human trial in which the drug rapamycin was used to treat skin aging with some promising results. HELP SPREAD THE WORD Please connect with us on social media, like and share our content, and help...
November 18, 2019
ResTORbio announced on Friday 15th that its current phase 3 drug trial for respiratory tract infections did not achieve its primary goal. The drug showed promise in earlier phases of testing, but sadly failed to reduce the incidence of respiratory tract infections in patients aged 65 and above. A setback for RTB101 This news has...
Mouse facing camera
July 24, 2019
Researchers have discovered a new drug that targets the mTOR pathway, which is involved in aging and metabolism. It could function as a caloric restriction mimetic, bringing about similar health benefits. The mTOR pathway The mechanistic target of rapamycin (mTOR) pathway is a part of metabolism and is one of the four major pathways that...
April 16, 2019
Rapamycin is a promising anti-aging therapeutic derived from a bacterium that was first found on Easter Island (it's named for Rapa Nui, the official name of Easter Island). It inhibits mTOR (mechanistic target of rapamycin), thus inhibiting the immune system response that would, in some cases, lead to organ rejection. This is the on-label, FDA-approved...
April 10, 2017
The biotechnology company PureTech are moving towards human clinical trials with a new therapy that may slow down the aging process and combat age-related disease. The company has licensed two new drug candidates, derivatives of the drug Rapamycin, from pharmaceutical giant Novartis. PureTech have recently announced a joint venture with Novartis called resTORbio and are...